The Medicines Company (MDCO) PT Trimmed to $50 at Leerink After Removing MDCO-216
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/26/2024
- Stocks face worst month since September, yen swings after BoJ
- Microsoft fiscal Q3 results top estimates as AI revolution spurs cloud growth
- Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
- Intel slides in afterhours trading as Q1 revenue misses, Q2 outlook falls short
- Oil prices on track to snap two-week losing streak
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- Union Pacific beats profit estimates on stronger pricing, resumes share buyback
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hertz Global (HTZ) misses earnings expectations as fleet costs weigh
- Teladoc (TDOC) Misses Q1 EPS by 3c, offers outlook
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
The Medicines Company Discontinues Development of MDCO-216, its Investigational Cholesterol Efflux Promoter
November 7, 2016 4:30 PM ESTTop-line efficacy data from the MILANO-PILOT trial, which enrolled 126 patients, provide insufficient basis for further investment by the Company
Discontinuation will enable the Company to reallocate and focus substantial additional capital onto the development of its PCSK9 synthesis inhibitor
Results from the MILANO-PILOT trial will be presented in the Late-Breaking Clinical Trial Session at American Heart Association Scientific Sessions 2016
PARSIPPANY, N.J.--(BUSINESS WIRE)-- The Medicines Company (NASDAQ: MDCO) announced today the immediate discontinuation of the clinical development program for MDCO-216, its investigational... More
